Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...

近几年双抗ADC研发火热，国内项目出海重磅交易不断。2023年12月百利天恒与BMS达成84亿美元的合作协议；2024年8月科伦博泰宣布默沙东行使双抗ADC药物SKB571项目的独家选择权，并支付3750万美元；以及，2024年11月橙帆医药与Ave ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

A key element of this mission is the company's "IO 2.0 + ADC" strategy. Akeso's self-developed, first-in-class bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), have both ...

This eBook explores the evolving ADC landscape, offering exclusive insights into clinical progress, regulatory approvals and ...

For example, the use of bispecific antibodies in place of the ... It is the second agreement in the ADC category for BMS in the last few weeks, coming after a smaller $180 million partnership ...

In June 2024, Jiangsu Alphamab entered into a research and collaboration agreement with ArriVent BioPharma, Inc. to use Jiangsu Alphamab's proprietary linker-payload (Alphatecan) and glycan-specific ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs  for ...

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline ...